HRP20211271T1 - Pripravci aripiprazolskog predlijeka - Google Patents

Pripravci aripiprazolskog predlijeka Download PDF

Info

Publication number
HRP20211271T1
HRP20211271T1 HRP20211271TT HRP20211271T HRP20211271T1 HR P20211271 T1 HRP20211271 T1 HR P20211271T1 HR P20211271T T HRP20211271T T HR P20211271TT HR P20211271 T HRP20211271 T HR P20211271T HR P20211271 T1 HRP20211271 T1 HR P20211271T1
Authority
HR
Croatia
Prior art keywords
aripiprazole prodrug
stabilizer
surface stabilizer
particles
composition
Prior art date
Application number
HRP20211271TT
Other languages
English (en)
Croatian (hr)
Inventor
Philip Cresswell
Magali Hickey
Elaine Liversidge
David Manser
Michael PALMIERI
Sara Montminy Paquette
Kristopher Perkin
Greg Smith
Brian STEINBERG
Ryan Turncliff
Tarek Zeidan
Ethan P. Cash
Marjie L. Hard
Original Assignee
Alkermes Pharma Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51352472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211271(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited
Publication of HRP20211271T1 publication Critical patent/HRP20211271T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20211271TT 2014-08-18 2015-08-17 Pripravci aripiprazolskog predlijeka HRP20211271T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038665P 2014-08-18 2014-08-18
EP14181328 2014-08-18
EP19154013.7A EP3508196B1 (en) 2014-08-18 2015-08-17 Aripiprazole prodrug compositions

Publications (1)

Publication Number Publication Date
HRP20211271T1 true HRP20211271T1 (hr) 2022-01-07

Family

ID=51352472

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211271TT HRP20211271T1 (hr) 2014-08-18 2015-08-17 Pripravci aripiprazolskog predlijeka

Country Status (20)

Country Link
US (1) US20220079939A1 (cg-RX-API-DMAC7.html)
EP (2) EP3182958B2 (cg-RX-API-DMAC7.html)
JP (1) JP6571166B2 (cg-RX-API-DMAC7.html)
CN (3) CN106794251B (cg-RX-API-DMAC7.html)
AU (1) AU2015306198B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002926A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124625T1 (cg-RX-API-DMAC7.html)
DK (1) DK3508196T3 (cg-RX-API-DMAC7.html)
ES (1) ES2884849T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211271T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055711T2 (cg-RX-API-DMAC7.html)
IL (2) IL292079B2 (cg-RX-API-DMAC7.html)
MX (1) MX371417B (cg-RX-API-DMAC7.html)
PL (2) PL3508196T3 (cg-RX-API-DMAC7.html)
PT (1) PT3508196T (cg-RX-API-DMAC7.html)
RS (2) RS58746B2 (cg-RX-API-DMAC7.html)
RU (1) RU2705376C2 (cg-RX-API-DMAC7.html)
SI (2) SI3182958T2 (cg-RX-API-DMAC7.html)
SM (2) SMT201900236T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016026822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3182958T (lt) * 2014-08-18 2019-06-25 Alkermes Pharma Ireland Limited Aripiprazolo provaisto kompozicijos
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
WO2017143017A1 (en) * 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
CN110025572A (zh) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 月桂酰阿立哌唑混悬剂及其制备方法
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
MX2023014507A (es) 2021-06-08 2024-01-26 Chugai Pharmaceutical Co Ltd Formulacion que contiene un derivado de dihidropiridazina-3,5-dion a.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
WO1997014407A1 (en) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
DK1443912T3 (da) * 2001-10-12 2008-01-21 Elan Pharma Int Ltd Sammensætninger med en kombination af umiddelbare og kontrollerede frisætningsegenskaber
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
EP1675573B2 (en) * 2003-10-23 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
EP2279727A3 (en) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
PL2445502T5 (pl) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych
PT2685979T (pt) * 2011-03-18 2016-12-02 Alkermes Pharma Ireland Ltd Composições farmacêuticas injetáveis compreendendo um antipsicótico solúvel em água, laurato de sorbitano e polissorbato 20
AU2013235526B2 (en) * 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9193685B2 (en) * 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability

Also Published As

Publication number Publication date
CY1124625T1 (el) 2022-07-22
CN112641785A (zh) 2021-04-13
DK3508196T3 (da) 2021-08-16
MX2017002029A (es) 2017-08-14
US20220079939A1 (en) 2022-03-17
CN112494492A (zh) 2021-03-16
JP2017524021A (ja) 2017-08-24
CN112494492B (zh) 2023-08-25
AU2015306198B2 (en) 2021-02-25
EP3182958B2 (en) 2022-05-18
BR112017002926A2 (pt) 2017-12-12
RS58746B2 (sr) 2022-07-29
NZ728914A (en) 2023-11-24
NZ767204A (en) 2024-02-23
CN106794251A (zh) 2017-05-31
CN106794251B (zh) 2020-12-29
IL292079A (en) 2022-06-01
SI3182958T1 (sl) 2019-05-31
EP3508196B1 (en) 2021-07-14
SMT202100481T1 (it) 2021-09-14
WO2016026822A1 (en) 2016-02-25
PL3508196T3 (pl) 2021-12-20
IL250607A0 (en) 2017-04-30
IL250607B (en) 2022-05-01
SI3508196T1 (sl) 2021-12-31
RU2017108204A (ru) 2018-09-21
PT3508196T (pt) 2021-08-25
AU2015306198A1 (en) 2017-03-02
CA2957762A1 (en) 2016-02-25
SMT201900236T1 (it) 2019-07-11
RS62232B1 (sr) 2021-09-30
EP3182958A1 (en) 2017-06-28
HUE055711T2 (hu) 2021-12-28
RS58746B1 (sr) 2019-06-28
IL292079B1 (en) 2024-03-01
JP6571166B2 (ja) 2019-09-04
SI3182958T2 (sl) 2022-07-29
MX371417B (es) 2020-01-29
ES2884849T3 (es) 2021-12-13
EP3182958B1 (en) 2019-02-27
RU2017108204A3 (cg-RX-API-DMAC7.html) 2019-04-04
PL3182958T3 (pl) 2019-07-31
PL3182958T5 (pl) 2022-09-12
EP3508196A1 (en) 2019-07-10
RU2705376C2 (ru) 2019-11-07
IL292079B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
HRP20211271T1 (hr) Pripravci aripiprazolskog predlijeka
Fabiańska et al. Biomarkers, aromatic hydrocarbons and polar compounds in the Neogene lignites and gangue sediments of the Konin and Turoszów Brown Coal Basins (Poland)
JP2016527665A5 (cg-RX-API-DMAC7.html)
MX2017001812A (es) Composiciones de formulacion liquida, aparatos de administracion de medicamentos, y metodos de preparacion y uso de los mismos.
AR093764A1 (es) Composiciones de limpieza que comprenden particulas estructuradas
JP2014129360A5 (cg-RX-API-DMAC7.html)
BR112016006789A2 (pt) composição acrílica endurecível de múltiplas partes, uso de uma primeira parte sólida de polímero acrílico, e, métodos para produzir um cimento acrílico e para produzir uma composição acrílica endurecível de múltiplas partes
MX362871B (es) Sílice funcionalizada con aglutinante de elastómero.
EA202090731A1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
BR112015029773A2 (pt) pós revestidos com aroma
JP2016135110A5 (cg-RX-API-DMAC7.html)
JP2017524021A5 (cg-RX-API-DMAC7.html)
MY173159A (en) Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
NZ720512A (en) Multi-particulate drug delivery system
EP2763060A3 (en) Simulation program, simulation method, and simulation device
EA201591826A1 (ru) Тонкодисперсные сухие композиции ретиноидного активного средства и содержащие их составы для местного применения
CL2016001761A1 (es) Proceso para reducir el flujo de volumen que comprende aglomerados magnéticos por elutriación.
PH12014501144A1 (en) Oil-in-water cosmetic compositions
GB2514741A (en) Composition for use as a paint binder
MY179602A (en) Curable composition, cured product, method for using curable composition, and optical device
RU2019134055A (ru) Композиции пролекарства арипипразола
MY186810A (en) Mixture of solvents for removing asphaltenes
NZ730713A (en) Dissolution testing of hydrophobic active pharmaceutical ingredients such as avermectins with or without pyrantel
Pal et al. Volumetric and acoustic studies of binary liquid mixtures of alkoxypropanols with methyl acetoacetate in the temperature interval 288.15–308.15 K
MX342418B (es) Un metodo para determinar o monitorear la cantidad o la distribucion de material adicional presente en un flujo de una sustancia fluible.